Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Claudin-23 (CLDN23)
- Target
- CLDN23
- Molecular classification
- Tight junction protein, Claudin family, Integral membrane protein, Other
01
Overview
Claudin-23 is an atypical, integral membrane protein within the claudin family, localized predominantly at the tight junctions of epithelial cells, particularly in the intestine. It plays a non-redundant role in strengthening and regulating epithelial barrier function by modulating the organization and permeability of tight junctions. CLDN23 associates with classical barrier-forming claudins (notably CLDN3 and CLDN4), recruiting them to tight junctions and promoting complex structural arrangements that reduce the paracellular flux of ions and macromolecules. While largely expressed in luminal intestinal epithelial cells, claudin-23 is also implicated in the neoplastic transformation of several cancers, including colorectal, gastric, and pancreatic cancer, and may have biomarker potential in these settings. No drugs are currently known to interact directly with claudin-23, and its candidacy as a direct therapeutic target is under preclinical investigation.
- Other names
- Claudin-23CLDN23CLDNLhCG16461632310014B08Rikclaudin-23
02
Mechanism of action
Not applicable/unknown. No drugs currently target claudin-23, so no mechanisms are established for drug targeting of this protein.
03
Biological functions
Regulation of epithelial barrier functionModulation of paracellular ion and macromolecule permeabilityFormation and structural organization of tight junctionsScaffolding of other claudins (e.g., CLDN3, CLDN4) into tight junctionsRegulation of mucosal barrier function in the gutPotential signaling roles in epithelial cell physiology
04
Disease associations
Cancer (e.g., gastric, pancreatic, colorectal cancer)Other disorders involving epithelial barrier dysfunction (e.g., gastrointestinal disorders, though direct evidence is still being developed)
05
Safety considerations
Not established. As claudin-23 is important for epithelial barrier function, disruption could theoretically lead to increased epithelial permeability or barrier dysfunction, especially in the gut. However, clinical safety issues are not documented.
06
Interacting drugs
None known. No approved or investigational drugs directly target claudin-23 as of 2024.
07
Biomarkers
Potential biomarker: CLDN23 expression has been noted in certain cancers (e.g., colorectal, gastric), suggesting possible biomarker utility for cancer diagnosis, prognosis, or molecular subtyping
Beyond the preview
Go deeper on Claudin-23 (CLDN23).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Claudin-23 (CLDN23).